Haemonetics Co. (NYSE:HAE) Shares Acquired by Zions Bancorporation N.A.

Zions Bancorporation N.A. increased its stake in Haemonetics Co. (NYSE:HAE) by 19.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,234 shares of the medical instruments supplier’s stock after acquiring an additional 4,278 shares during the quarter. Zions Bancorporation N.A. owned approximately 0.05% of Haemonetics worth $2,109,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Silvercrest Asset Management Group LLC acquired a new position in shares of Haemonetics in the 1st quarter worth $38,706,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Haemonetics by 38.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after acquiring an additional 156,665 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Haemonetics by 311.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier’s stock worth $2,132,000 after acquiring an additional 19,510 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Haemonetics by 26.8% in the 1st quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock worth $2,536,000 after acquiring an additional 6,287 shares during the last quarter. Finally, CWM LLC grew its holdings in shares of Haemonetics by 40.5% in the 2nd quarter. CWM LLC now owns 36,526 shares of the medical instruments supplier’s stock worth $3,022,000 after acquiring an additional 10,537 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HAE has been the subject of several recent analyst reports. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 13th. Bank of America initiated coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price for the company. BTIG Research initiated coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 target price for the company. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Price Performance

HAE opened at $90.75 on Friday. The stock has a market cap of $4.56 billion, a price-to-earnings ratio of 37.66, a PEG ratio of 1.43 and a beta of 0.32. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The stock has a fifty day moving average price of $76.90 and a 200 day moving average price of $82.71.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same quarter in the previous year, the firm earned $0.99 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.